The stock of Bionano Genomics Inc. (NASDAQ:BNGO) last traded at $0.62, down -2.97% from the previous session.
Data from the available sources indicates that Bionano Genomics Inc. (NASDAQ:BNGO) is covered by 6 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $7.50 and a low of $1.75, we find $3.00. Given the previous closing price of $0.64, this indicates a potential upside of 368.75 percent. BNGO stock price is now -8.06% away from the 50-day moving average and -55.78% away from the 200-day moving average. The market capitalization of the company currently stands at $193.06M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
In total, 0 analysts have assigned it a hold rating, and 6 have given it a buy rating. Brokers who have rated the stock have averaged $3.68 as their price target over the next twelve months.
With the price target of $4, Scotiabank recently initiated with Sector Outperform rating for Bionano Genomics Inc. (NASDAQ: BNGO).
In other news, Mamuszka Hannah, Director bought 65,789 shares of the company’s stock on Jun 13. The stock was bought for $50,000 at an average price of $0.76. Upon completion of the transaction, the Director now directly owns 65,789 shares in the company, valued at $40789.18. An SEC document containing details of the transaction can be found on the SEC’s website. On May 16, President and CEO Holmlin R. Erik bought 15,000 shares of the business’s stock. A total of $9,639 was incurred on buying the stock at an average price of $0.64. This leaves the insider owning 806,474 shares of the company worth $0.5 million. Insiders disposed of 111,637 shares of company stock worth roughly $69214.94 over the past 1 year. A total of 1.82% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BNGO stock. A new stake in Bionano Genomics Inc. shares was purchased by QUADRATURE CAPITAL LTD during the first quarter worth $107,000. SEI INVESTMENTS CO invested $24,000 in shares of BNGO during the first quarter. In the first quarter, IVC WEALTH ADVISORS LLC acquired a new stake in Bionano Genomics Inc. valued at approximately $18,000. CERTIFIED ADVISORY CORP acquired a new stake in BNGO for approximately $10,000. AIGEN INVESTMENT MANAGEMENT, LP purchased a new stake in BNGO valued at around $9,000 in the second quarter. In total, there are 212 active investors with 27.30% ownership of the company’s stock.
With an opening price of $0.6473 on Tuesday morning, Bionano Genomics Inc. (NASDAQ: BNGO) set off the trading day. During the past 12 months, Bionano Genomics Inc. has had a low of $0.55 and a high of $4.35. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 3.70, and a quick ratio of 2.90. The fifty day moving average price for BNGO is $0.6790 and a two-hundred day moving average price translates $1.4061 for the stock.
The latest earnings results from Bionano Genomics Inc. (NASDAQ: BNGO) was released for Mar, 2023. According to the Medical Instruments & Supplies Company, earnings per share came in at -$0.12, missing analysts’ expectations of -$0.11 by -0.01. This compares to -$0.11 EPS in the same period last year. The company reported revenue of $7.42 million for the quarter, compared to $5.7 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 30.18 percent. For the current quarter, analysts expect BNGO to generate $8.29M in revenue.
Bionano Genomics Inc.(BNGO) Company Profile
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
